Please assess the completion status of the following clinical trial:

Trial Title: EMERALD: Effects of Metformin on Cardiovascular Function in Adolescents With Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adolescents 12-21 years of age with type 1 diabetes (defined as having positive antibodies as well as insulin requirement)~2. Willing to consent for participation in study~3. Body Mass Index (BMI) \>5% on growth charts~Exclusion Criteria:~1. Current use of medications known to affect insulin sensitivity: oral glucocorticoids within 10 days, atypical antipsychotics, immunosuppressant agents, metformin or thiazolidinediones.~2. Currently pregnant or breastfeeding women~3. Use of a thiazolidinedione within 12 weeks~4. Severe illness or Diabetic Ketoacidosis within 60 days~5. Macroalbuminuria~6. Hemoglobin A1c \> 12%~7. Weight \> 136.4 kg or \< 42 kg, BMI \< 5%~8. Creatinine \> 1.2~9. Hemoglobin \< 9~10. Major psychiatric or developmental disorder limiting informed consent~11. Implanted metal devices~12. Inability to tolerate ≥500mg twice a day of metformin

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Metformin (Type: EXPERIMENTAL): Metformin will be given at a dose of 1000 mg twice a day orally for three months to assess changes in insulin resistance compared to placebo.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo will be given at a dose of 1000 mg twice a day orally for three months to assess changes in insulin resistance compared to metformin.

Based on this trial design, predict the completion outcome and termination type (if applicable).